The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

ABSTRACT:

Objectives

Therapies to achieve sustained antiretroviral therapy-free HIV remission will require validation in analytic treatment interruption (ATI) trials. Identifying biomarkers that predict time to viral rebound could accelerate the development of such therapeutics.

Design

A pooled analysis of participants from six AIDS Clinical Trials Group ATI studies to identify predictors of viral rebound.

Methods

Cell-associated DNA (CA-DNA) and CA-RNA were quantified in pre-ATI peripheral blood mononuclear cell samples, and residual plasma viremia was measured using the single-copy assay.

Results

Participants who initiated antiretroviral therapy (ART) during acute/early HIV infection and those on a non-nucleoside reverse transcriptase inhibitor-containing regimen had s

SUBMITTER: Li JZ 

PROVIDER: S-EPMC4840470 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature